Characteristic | Placebo (n = 500) | Peginterferon beta-1a 125 μg every 4 weeks | Peginterferon beta-1a 125 μg every 2 weeks |
---|---|---|---|
(n = 500) | (n = 512) | ||
Age, years | 36.3 (9.74) | 36.4 (9.87) | 36.9 (9.79) |
Gender, % female | 72 | 70 | 71 |
Time since first MS symptoms, years | 6.3 (6.28) | 6.5 (6.07) | 6.9 (6.61) |
Relapses within the previous 12Â months | 1.6 (0.67) | 1.5 (0.62) | 1.6 (0.67) |
EDSS Score | 2.44 (1.18) | 2.48 (1.24) | 2.47 (1.26) |
Number who took any prior MS medicationa, n (%) | 86 (17) | 85 (17) | 89 (17) |
No Gd+ lesions, n (%) | 296 (59) | 297 (59) | 334 (65) |
Number of T2 lesions | 50.6 (35.7) | 51.4 (36.0) | 48.7 (36.8) |
Number of T1 hypointense lesions | 28.1 (29.2) | 29.6 (30.8) | 27.8 (28.1) |
Number of Gd+ lesions | 1.6 (3.81) | 1.8 (5.38) | 1.2 (3.44) |
Volume of T2 lesions, cm3 | 10.1 (11.9) | 11.3 (13.2) | 9.8 (11.6) |
Volume of T1 hypointense lesions, cm3 | 3.1 (4.80) | 3.1 (4.76) | 3.0 (4.50) |